Applicants: Daniel J. Capon et al.

Serial No.: 09/126,559 June 30, 1998 Filed:

Page 2

ð

in a continuation or divisional application. Please amend claims

1, 8, 55 and 57 as follows:

method for determining 1. (2X Amended) the susceptibility of hepatitis C viral replication to an anti-hepatitis C virus drug comprising:

- culturing a host cell in the presence of the anti-hepatitis C virus drug, wherein the host cell has introduced thereto a resistance test vector comprising (i) a patient-derived segment comprising a hepatitis C virus gene and (ii) an indicator geng, wherein the expression of the indicator gene is dependent upon the patientderived segment;
- measuring the expression of the indicator gene in (b) the host cell from step (a); and
- comparing the expression of the indicator gene as (C) measured in step (b) with the expression of the indicator gene measured in the host cell of step (a) cultured in the absence of the anti-hepatitis C virus drug, whereby greater expression of the indicator gene measured in step (c) relative to that / measured in step (b) indicates susceptibility of hepatitis C viral replication to The anti-hepatitis C virus drug.

8.

The method of claim 1, wherein the patient-(Amend a sagment comprises a viral sequence comprising internal ribosome entry site.

(2X Amended) # method for determining anti-hepatitis 55. C virus drug resistance in a patient comprising:

deveroping standard of drug curve

Applicants: Daniel J. Capon et al.

Serial No.: 09/126,559 Filed: June 30, 1998

Page 3

susceptibility for an anti-hepatitis C virus drug;

- (b) determining the susceptibility to the antihepatitis C virus drug in the patient according to the method of claim 1; and
- (c) comparing the anti-hepatitis C virus drug susceptibility determined in step (b) with the standard curve of step (a), whereby anti-hepatitis C drug susceptibility which is decreased relative to that shown by the standard curve indicates anti-hepatitis C drug resistance in the patient.
- 57. (Twice Amended) A method for determining antihepatitis C virus drug resistance in a patient comprising:
 - (a) determining in the patient the susceptibility to an anti-hepatitis C virus drug at a first time point according to the method of claim 1, wherein the patient-derived segment is obtained from the patient at about the same time as the first time point;
 - (b) determining in the patient the susceptibility to the anti-hepatitis C virus drug at a second time point; and
 - (c) comparing the anti-hepatitis C virus drug susceptibilities determined in steps (a) and (b), wherein a decrease in anti-hepatitis C drug susceptibility at the second time point relative to that of the first time point indicates antihepatitis C virus drug resistance in the patient.

13

ŕ